San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Aethlon Subsidiary to Collaborate With Thomas Jefferson University in Cancer Research

San Diego-based Aethlon Medical Inc., a company developing targeted therapeutic devices to address infectious diseases and cancer, announced that its majority-owned subsidiary Exosome Sciences Inc. has entered into a research collaboration with Thomas Jefferson University.

By Brittany Meiling April 3, 2015 1:04 p.m.   Share

NuVasive Reports Q2 Net Income of $10.3 Million

NuVasive Inc. on Tuesday reported second-quarter net income of $10.3 million, after reporting a loss in the same period a year earlier.

UCSD, La Jolla Institute for Allergy and Immunology Sign Agreement

The La Jolla Institute for Allergy and Immunology announced Monday an official affiliation agreement with the University of California, San Diego Health System.

Salk Institute's President, William Brody, Retiring

William Brody will retire at the end of the year as president of the Salk Institute for Biological Studies in La Jolla, opening up a third major leadership position in San Diego’s science community.

VetStem and Animal Hospital Announce Partnership

Poway-based VetStem Biopharma, a veterinary regenerative medicine company, and VCA Emergency Animal Hospital & Referral Center recently announced an educational and clinical partnership in support of local area vets.

Quidel Corp. Reports Q2 Revenue is Up 11 Percent

Quidel Corp. reported that revenue was up 11 percent for the second quarter of 2015, according to a recent earnings statement.

Biotechs Insulate Region as IPO Market Cools

BIOTECH: Surge in Private Financing Allows Some Cos. to Put Off IPO

The once white-hot market for initial public offerings in the U.S. has cooled in recent months as private companies stay private longer or opt to be taken out by larger rivals. But the local biotechnology scene may be insulating San Diego from the trend.

Lpath Inc. Initiating Phase 1 Clinical Trial of Key Antibody

San Diego-based Lpath Inc. announced that it’s initiating a Phase 1 clinical trial to study Lpathomab within the next two months.

Illumina Records Q2 Revenue of $539 Million

Shares of Illumina Inc. have fallen nearly 10 percent this week after the gene-sequencing company announced second-quarter revenue missed analysts’ expectations on Tuesday.

Forge Therapeutics, Janssen to Conduct Pilot Study

Forge Therapeutics Inc., a biotechnology startup in San Diego, announced Tuesday that it has entered into a pilot study with Janssen Research & Development LLC.

Biopharmaceutical Startup Dauntless Announces $12M Series A Financing

Dauntless Pharmaceuticals Inc., a new biopharmaceutical company focused on the development of specialty drugs, announced Tuesday the closing of a $12 million Series A financing.

George Uy Leaving Sorrento Therapeutics for New Startup

Sorrento Therapeutics Inc., a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced that George Uy, executive vice president and chief commercial officer, will leave the company at the end of July to join a startup as its chief executive officer.

Trovagene Aims to Raise $35M With Common Stock Offering

San Diego-based Trovagene Inc., a molecular diagnostics company, announced July 17 an offering of 4 million shares of its common stock, which is expected to bring in gross proceeds of around $35 million.

Tom Gruber Named New CEO at MyDx Inc.

MyDx Inc., creator of a handheld chemical analyzer for consumers, has appointed Tom Gruber as the new chief executive officer effective July 10, 2015.

Viviano’s Departure Won’t Slow UCSD Health’s Building Boom

UC San Diego Health System is losing its well-respected chief executive officer, Paul Viviano, but hospital officials say the loss won’t delay its building boom.

Tease photo

Sale of High-Flying Receptos Could Fuel More Innovation

BIOTECH: Talent Likely to Start New Ventures

In one of the largest sales of a San Diego biotech to date, New Jersey-based drug maker Celgene has agreed to purchase Receptos Inc. for $7.2 billion.